DE69524241D1 - 2,7,-substituierte octahydro-1h-pyrido[1,2-a]pyrazin derivate - Google Patents

2,7,-substituierte octahydro-1h-pyrido[1,2-a]pyrazin derivate

Info

Publication number
DE69524241D1
DE69524241D1 DE69524241T DE69524241T DE69524241D1 DE 69524241 D1 DE69524241 D1 DE 69524241D1 DE 69524241 T DE69524241 T DE 69524241T DE 69524241 T DE69524241 T DE 69524241T DE 69524241 D1 DE69524241 D1 DE 69524241D1
Authority
DE
Germany
Prior art keywords
pct
pyrido
pyrazine derivatives
sec
substituted octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69524241T
Other languages
English (en)
Other versions
DE69524241T2 (de
Inventor
A Desai
F Fliri
A Sanner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69524241D1 publication Critical patent/DE69524241D1/de
Publication of DE69524241T2 publication Critical patent/DE69524241T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69524241T 1994-09-30 1995-08-24 2,7,-substituierte octahydro-1h-pyrido[1,2-a]pyrazin derivate Expired - Lifetime DE69524241T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31547094A 1994-09-30 1994-09-30
PCT/IB1995/000689 WO1996010571A1 (en) 1994-09-30 1995-08-24 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1,2-a]PYRAZINE DERIVATIVES

Publications (2)

Publication Number Publication Date
DE69524241D1 true DE69524241D1 (de) 2002-01-10
DE69524241T2 DE69524241T2 (de) 2002-06-13

Family

ID=23224581

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69524241T Expired - Lifetime DE69524241T2 (de) 1994-09-30 1995-08-24 2,7,-substituierte octahydro-1h-pyrido[1,2-a]pyrazin derivate

Country Status (34)

Country Link
US (1) US5852031A (de)
EP (1) EP0783503B1 (de)
JP (1) JP3287574B2 (de)
KR (1) KR100244848B1 (de)
CN (1) CN1068327C (de)
AT (1) ATE209648T1 (de)
AU (1) AU681310B2 (de)
BR (1) BR9504230A (de)
CA (1) CA2200959C (de)
CO (1) CO4410335A1 (de)
CZ (1) CZ285090B6 (de)
DE (1) DE69524241T2 (de)
DK (1) DK0783503T3 (de)
ES (1) ES2166830T3 (de)
FI (1) FI113655B (de)
HR (1) HRP950507B1 (de)
HU (1) HUT77354A (de)
IL (1) IL115384A (de)
MX (1) MX9702350A (de)
MY (1) MY113729A (de)
NO (1) NO308995B1 (de)
NZ (1) NZ290936A (de)
PE (1) PE47196A1 (de)
PL (1) PL180899B1 (de)
PT (1) PT783503E (de)
RU (1) RU2163239C2 (de)
SI (1) SI9520096A (de)
SK (1) SK284341B6 (de)
TR (1) TR199501194A2 (de)
TW (1) TW406081B (de)
UA (1) UA50720C2 (de)
WO (1) WO1996010571A1 (de)
YU (1) YU63795A (de)
ZA (1) ZA958223B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
ATE205846T1 (de) * 1995-12-21 2001-10-15 Pfizer 2,7-substituierte octahydropyrrolo(1,2- a)pyrazinderivate
US6281216B1 (en) * 1998-02-09 2001-08-28 Duphar International Research B.V. 2-aminoquinoline derivatives having d4-agonistic activity
EP0953567A3 (de) 1998-04-29 2003-04-02 Pfizer Products Inc. Bizyklisch substituierte Piperazin-, Piperidin- und Tetrahydropyridin Derivate, deren Herstellung und deren Verwendung als Mittel mit zentraler dopaminerger (Dopamin D4 Rezeptor) Aktivität
GT199900060A (es) * 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) * 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
EP1177792A3 (de) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamin-d4-ligande zur behandlung von gaudi-suchenden krankheiten
US6670476B2 (en) 2000-11-29 2003-12-30 Pfizer Inc. Resolution of trans-7-(hydroxy-methyl)octa-hydro-2H-pyrido[1,2-a]pyrazine
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3388128A (en) * 1965-09-03 1968-06-11 Allan R. Day Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4517187A (en) * 1982-10-18 1985-05-14 Pennwalt Corporation 1,3,4,6,7-11b-Hexahydro-7-phenyl-2H-pyrazino[2,1-a]isoquinolines methods of preparation, and use as antidepressants
EP0173634B1 (de) * 1984-08-07 1988-08-31 Cortial S.A. 4-(Arylpiperazinylethylaminoethoxy)-phenolderivate, Verfahren zu deren Herstellung und deren therapeutische Verwendung
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
IT1204803B (it) * 1986-02-17 1989-03-10 Acraf Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono,procedimento per prepararlo e intermedio utile in detto procedimento
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
EP0569387B1 (de) * 1991-01-31 1995-04-05 Pfizer Inc. Recematspaltung von trans-2-(2-pyrimidinyl)-7-(hydroxymethyl)octahydro-2h-pyrido[1,2-a]-pyrazin.
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
US5185449A (en) * 1991-02-27 1993-02-09 Pfizer Inc. Process and intermediate for certain bis-aza-bicyclic anxiolytic agents
ATE150453T1 (de) * 1991-02-27 1997-04-15 Pfizer Verfahren zur herstellung von trans-piperidin-2,5-dicarboxylaten
ES2096099T3 (es) * 1991-09-25 1997-03-01 Pfizer Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
DK0646116T3 (da) * 1992-06-16 1999-12-27 Pfizer Fremgangsmåde og mellemprodukter til fremstilling af bis-aza-bicycliske anxiolytiske midler
WO1994010162A1 (en) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
AU678186B2 (en) * 1992-10-23 1997-05-22 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
WO1994020497A1 (en) * 1993-03-01 1994-09-15 Merck Sharp & Dohme Limited Pyrrolo-pyridine derivatives
US5576319A (en) * 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
AU679040B2 (en) * 1993-03-01 1997-06-19 Merck Sharp & Dohme Limited Pyrrolo-pyridine derivatives as dopamine receptor ligands
JPH08508466A (ja) * 1993-03-05 1996-09-10 メルク シヤープ エンド ドーム リミテツド ドーパミンｄ４リガンドとしてのキノロン誘導体
GB9416162D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
SI9520096A (sl) 1998-04-30
EP0783503A1 (de) 1997-07-16
WO1996010571A1 (en) 1996-04-11
DE69524241T2 (de) 2002-06-13
KR970706282A (ko) 1997-11-03
PL180899B1 (pl) 2001-04-30
JPH09511527A (ja) 1997-11-18
ZA958223B (en) 1997-04-01
UA50720C2 (uk) 2002-11-15
ES2166830T3 (es) 2002-05-01
RU2163239C2 (ru) 2001-02-20
MX9702350A (es) 1997-06-28
MY113729A (en) 2002-05-31
AU681310B2 (en) 1997-08-21
TR199501194A2 (tr) 1996-06-21
PE47196A1 (es) 1996-11-11
CA2200959C (en) 2000-05-23
CZ285090B6 (cs) 1999-05-12
JP3287574B2 (ja) 2002-06-04
HRP950507A2 (en) 1997-08-31
HRP950507B1 (en) 2002-06-30
DK0783503T3 (da) 2002-02-11
CA2200959A1 (en) 1996-04-11
AU3189395A (en) 1996-04-26
EP0783503B1 (de) 2001-11-28
NO308995B1 (no) 2000-11-27
SK284341B6 (sk) 2005-02-04
US5852031A (en) 1998-12-22
PT783503E (pt) 2002-03-28
YU63795A (sh) 1999-03-04
BR9504230A (pt) 1996-08-06
TW406081B (en) 2000-09-21
SK32597A3 (en) 1998-09-09
CN1168672A (zh) 1997-12-24
FI971310A0 (fi) 1997-03-27
FI113655B (fi) 2004-05-31
IL115384A0 (en) 1995-12-31
NZ290936A (en) 1998-01-26
CN1068327C (zh) 2001-07-11
KR100244848B1 (ko) 2000-03-02
IL115384A (en) 1999-10-28
PL319636A1 (en) 1997-08-18
CO4410335A1 (es) 1997-01-09
NO971416L (no) 1997-05-20
FI971310A (fi) 1997-03-27
CZ94797A3 (cs) 1998-07-15
HUT77354A (hu) 1998-03-30
NO971416D0 (no) 1997-03-25
ATE209648T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
GR3015144T3 (en) Quinuclidine derivatives.
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
AP1456A (en) Pharmaceutical agents for the treatment of parkinson's disease, ADHD and microadenomas.
DE69524241D1 (de) 2,7,-substituierte octahydro-1h-pyrido[1,2-a]pyrazin derivate
SE9703414D0 (sv) New compounds
HUP0003118A2 (hu) 2,7-Szubsztituált oktahidro-1H-pirido-[1,2-a]pirazin-származékok alkalmazása gyógyszerkészítmények előállítására
AU693241B2 (en) New 3-substituted 3h-2,3-benzodiazepine derivatives, their preparation and use as medicaments
DE69215886D1 (de) NEUROLEPTISCH 2-SUBSTITUIERTE PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINE
MXPA03002914A (es) Compuestos quimicos.
DE59209939D1 (de) ANTIALLERGISCHE THIADIAZOLO(4,3-a)PYRIDINDERIVATIVE
AR021502A1 (es) Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso
ES2119454T3 (es) Derivados de pirrolidina para el tratamiento de los desordenes relacionados con la csk y la gastrina.
MX9102181A (es) Iminobenzodiazepina para el tratamiento de desordenes del sueno

Legal Events

Date Code Title Description
8364 No opposition during term of opposition